Ninlaro
Active Ingredient(s): IxazomibFDA Approved: * November 20, 2015
Pharm Company: * MILLENNIUM PHARMS
Category: Cancer
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma,[2] a type of white blood cell cancer,[3] in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug wa... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.